BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22890802)

  • 1. 3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy.
    Ferrari ME; Cremonesi M; Di Dia A; Botta F; De Cicco C; Sarnelli A; Pedicini P; Calabrese M; Orecchia R; Pedroli G; Paganelli G
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1702-11. PubMed ID: 22890802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin.
    Paganelli G; De Cicco C; Ferrari ME; Carbone G; Pagani G; Leonardi MC; Cremonesi M; Ferrari A; Pacifici M; Di Dia A; De Santis R; Galimberti V; Luini A; Orecchia R; Zurrida S; Veronesi U
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):203-11. PubMed ID: 19760414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer.
    Paganelli G; Ferrari M; Ravasi L; Cremonesi M; De Cicco C; Galimberti V; Sivolapenko G; Luini A; De Santis R; Travaini LL; Fiorenza M; Chinol M; Papi S; Zanna C; Carminati P; Veronesi U
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5646s-5651s. PubMed ID: 17875802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation.
    Paganelli G; Ferrari M; Cremonesi M; De Cicco C; Galimberti V; Luini A; Veronesi P; Fiorenza M; Carminati P; Zanna C; Orecchia R; Veronesi U
    Breast; 2007 Feb; 16(1):17-26. PubMed ID: 17174093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin.
    Paganelli G; De Cicco C; Ferrari ME; McVie G; Pagani G; Leonardi MC; Cremonesi M; Ferrari A; Pacifici M; Di Dia A; Botta F; De Santis R; Galimberti V; Luini A; Orecchia R; Veronesi U
    Ecancermedicalscience; 2010; 4():166. PubMed ID: 22276027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
    Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation With Treatment Efficacy.
    Song YS; Paeng JC; Kim HC; Chung JW; Cheon GJ; Chung JK; Lee DS; Kang KW
    Medicine (Baltimore); 2015 Jun; 94(23):e945. PubMed ID: 26061323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
    Dewaraja YK; Schipper MJ; Roberson PL; Wilderman SJ; Amro H; Regan DD; Koral KF; Kaminski MS; Avram AM
    J Nucl Med; 2010 Jul; 51(7):1155-62. PubMed ID: 20554734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of a large number of clinical studies for breast cancer radiotherapy: estimation of radiobiological parameters for treatment planning.
    Guerrero M; Li XA
    Phys Med Biol; 2003 Oct; 48(20):3307-26. PubMed ID: 14620060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Averaging of absorbed doses: How matter matters.
    Gustafsson J; Ljungberg M; Alm Carlsson G; Larsson E; Warfvinge CF; Asp P; Sjögreen Gleisner K
    Med Phys; 2023 Oct; 50(10):6600-6613. PubMed ID: 37272586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres.
    Dieudonné A; Garin E; Laffont S; Rolland Y; Lebtahi R; Leguludec D; Gardin I
    J Nucl Med; 2011 Dec; 52(12):1930-7. PubMed ID: 22068894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 90Y PET-based dosimetry after selective internal radiotherapy treatments.
    D'Arienzo M; Chiaramida P; Chiacchiararelli L; Coniglio A; Cianni R; Salvatori R; Ruzza A; Scopinaro F; Bagni O
    Nucl Med Commun; 2012 Jun; 33(6):633-40. PubMed ID: 22407156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response.
    Plyku D; Hobbs RF; Wu D; Garcia C; Sgouros G; Van Nostrand D
    Ann Nucl Med; 2022 Mar; 36(3):213-223. PubMed ID: 35119623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
    Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
    Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer.
    Adam DP; Grudzinski JJ; Marsh IR; Hill PM; Cho SY; Bradshaw TJ; Longcor J; Burr A; Bruce JY; Harari PM; Bednarz BP
    Int J Radiat Oncol Biol Phys; 2024 Feb; ():. PubMed ID: 38367914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.